Conclusion: Although CO2-enhanced US requires angiography, it was superior to both Sonazoid-enhanced US and conventional US for detecting tumor residues, particularly deep-seated ones, after percutaneous RF ablation.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Background/Aims: This study's purpose was to compare the efficacy of CO2-enhanced ultrasonography (US) with that of Sonazoid-enhanced US and conventional US in detecting local tumor residue after percutaneous radiofrequency (RF) ablation therapy for hepatocellular carcinoma.Materials and Methods: Between February 2009 and March 2010, 141 lesions of 121 hepatocellular carcinoma patients were treated by percutaneous RF ablation, and 22 tumor residues were detected in 22 patients by contrast-enhanced computed tomography.
📊
Temel Bulgular & Veri:These 22 patients were examined by conventional US, Sonazoidenhanced US (0.5 mL/body of Sonazoid, intravenous administration), and CO2-enhanced US (10 mL of CO2, hepatic arterial administration).Results: Tumor residue was confirmed by CO2-enhanced US in all the 22 patients (sensitivity: 100%) in 19 of the 22 patients by Sonazoid-enhanced US (sensitivity: 86%; 3 lesions that were not detected by this modality were located deeper than the sonographic depth (p=0.0109)), and in 17 of the 22 patients by conventional US (sensitivity: 77%; 5 lesions that were not detected by this modality were smaller in terms of the sonographic tumor size (p=0.0278)).
💡
Sonuç & Katkı:Conclusion: Although CO2-enhanced US requires angiography, it was superior to both Sonazoid-enhanced US and conventional US for detecting tumor residues, particularly deep-seated ones, after percutaneous RF ablation.
🔬Tür:Araştırma Makalesi
📍Kapsam:2009 Verileri
⚙️Değişkenler:Alan Parametreleri
Özet
Background/Aims: This study's purpose was to compare the efficacy of CO2-enhanced ultrasonography (US) with that of Sonazoid-enhanced US and conventional US in detecting local tumor residue after percutaneous radiofrequency (RF) ablation therapy for hepatocellular carcinoma.Materials and Methods: Between February 2009 and March 2010, 141 lesions of 121 hepatocellular carcinoma patients were treated by percutaneous RF ablation, and 22 tumor residues were detected in 22 patients by contrast-enhanced computed tomography. These 22 patients were examined by conventional US, Sonazoidenhanced US (0.5 mL/body of Sonazoid, intravenous administration), and CO2-enhanced US (10 mL of CO2, hepatic arterial administration).Results: Tumor residue was confirmed by CO2-enhanced US in all the 22 patients (sensitivity: 100%) in 19 of the 22 patients by Sonazoid-enhanced US (sensitivity: 86%; 3 lesions that were not detected by this modality were located deeper than the sonographic depth (p=0.0109)), and in 17 of the 22 patients by conventional US (sensitivity: 77%; 5 lesions that were not detected by this modality were smaller in terms of the sonographic tumor size (p=0.0278)). Conclusion: Although CO2-enhanced US requires angiography, it was superior to both Sonazoid-enhanced US and conventional US for detecting tumor residues, particularly deep-seated ones, after percutaneous RF ablation.
🔖
Bu Makaleye Atıf Yap
HAMANAKA, J., GOTO, T., NİSHİGORİ, S., SEKİ, S., IDA, T., MOROHASHİ, T., OHARA, H., INAMORİ, M., MAEDA, S. (2017). Evaluation of local tumor residue after percutaneous radiofrequency ablation therapy for hepatocellular carcinoma. Turkish Journal of Gastroenterology, Cilt: 28 - Sayı: 3, 197–201. https://ajindex.com/articles/410165
Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014; 109: 542-53. [CrossRef ] Metts J, Carmichael L, Kokor W, Scharffenberg R. Hepatitis C: prev- alence, transmission, screening, and prevention. FP Essent 2014; 427: 11-7.
Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012; 1: 144-58. [CrossRef ] Lee DH, Lee JM, Lee JY, et al. Radiofrequency ablation of hepato- cellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology 2014; 270: 900-9. [CrossRef ] Matsuda Y, Yabuuchi I. Hepatic tumors: US contrast enhancement with CO2 microbubbles. Radiology 1986; 161: 701-5. [CrossRef ] Leen E, McArdle CS. Ultrasound contrast agents in liver imaging. Clin Radiol 1996; 51: 35-9.
Harvey CJ, Blomley MJK, Eckersley RJ, Cosgrove DO. Develop- ments in ultrasound contrast media. Eur Radiol 2001; 11: 675-89. [CrossRef ] Numata K, Luo W, Morimoto M, et al. Contrast enhanced ultra- sound of hepatocellular carcinoma. World J Radiol 2010; 2: 68-82. [CrossRef ] Akiyama T, Inamori M, Saito S, et al. Levovist ultrasonography im- aging in intracystic hemorrhage of simple liver cyst. World J Gas- troenterol 2008; 14: 805-7. [CrossRef ] Shirato K, Morimoto M, Tomita N, et al. Hepatocellular carcinoma: therapeutic experience with percutaneous ethanol injection un- der real-time contrast-enhanced color Doppler sonography with the contrast agent Levovist. J Ultrasound Med 2002; 21: 1015-22. [CrossRef ] Luo W, Numata K, Morimoto M, et al. Clinical utility of contrast- enhanced three-dimensional ultrasound imaging with Sonazoid: findings on hepatocellular carcinoma lesions. Eur J Radiol 2009; 72: 425-31. [CrossRef ] Shiozawa K, Watanabe M, Takayama R, et al. Evaluation of local tumor residue after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography. J Clin Ultrasound 2010; 38: 182-9.
Marone G, Francica G, D'Angelo V, et al. Echo-guided radiofre- quency percutaneous ablation of hepatocellular carcinoma in cirrhosis using a cooled needle. Radiol Med 1998; 95: 624-9.
Kirikoshi H, Saito S, Yoneda M, et al. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular car